Table 3

Clinical course and treatment-related morbidity in patients with SSc not responding to autologous SCT

Anti-double-

Steroid

Karnofsky

Side effects

Follow-up

stranded DNA:

dosage

score

during

Patient^*

(months)

ANA^†

ELISA^†‡ (iU/ml)

Scl 70^†

(mg/day)^†§

(%)^†

Skin score^†

immunoablation

5

13

5120

2.8

+

Refused

60

19

SIRS^¶: WHO grade II

Female/23 years/

↓

↓

↓

steroids

↓

↓

Isolated reduction of

1987

2560

None

+

60

19

F VII to 3% (Q 21%)

6

6

5120

None

+

20

70

30

SIRS^¶: WHO grade II

Male/25 years/

↓

↓

↓

↓

↓

↓

1995

2560

None

+

20

70

30

7

None

2560

None

+

30

40

32

Fluid retention during

Female/45 years/

↓

↓

↓

↓

↓

↓

preparative regimen

1996

NE

NE

NE

NE

NE

NE

^*Characteristics: sex/age/year of diagnosis. ^† Values above the arrow represent the admission values and those below the arrow represent the present status. ^‡ELISA cut-off was 118 iU/ml. ^§Doses corresponding to prednisolone equivalents. ^¶SIRS due to application of cyclophosphamide and ATG. ELISA, enzyme-linked immunosorbent assay; F VII, blood clotting factor VII; NE, not evaluable; Q, Quick's value (reciprocal value of prothrombin time of the test sample compared with that of normal plasma as percentage); SIRS, systemic inflammatory response syndrome; WHO, World Health Organization.

Rosen et al. Arthritis Res 2000 2:327   doi:10.1186/ar107